# US 2022/0090081 A1 · Novel dna aptamer and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0090081 A1
- Document ID: US20220090081A1
- Status: Published application
- Kind: A1
- Application number: 17/416,858
- Filed: 2019-08-08
- Published: 2022-03-24
- Earliest claimed: 2018-12-21
- Assignees: Jp Bio A Inc.; National Cancer Center
- Applicants: Jp Bio A Inc.; National Cancer Center
- Inventors: Yun Hee KIM; Kyun HEO; Sun II CHOI; In Hoo KIM
- Web page: https://patentgrep.com/patent/US20220090081A1

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/16: Aptamers
- C12N 2310/321: 2'-O-R Modification
- C12N 2320/13: in a process of directed evolution, e.g. SELEX, acquiring a new function
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to novel DNA aptamers and use thereof. In particular, the present disclosure relates to DNA aptamers selected from a DNA library using Cell-SELEX to bind specifically to cancer cells. The DNA aptamers of the present disclosure selected and optimized for high binding affinity to cancer cells can be effectively used for the diagnosis of cancer as they have enhanced targeting efficiencies for target cells and tissues as well as high serum stability.

## Claims

### Claim 1

A DNA aptamer comprising a nucleotide sequence having at least 90% homology to the nucleotide sequence of SEQ ID NO: 6.

### Claim 2 (depends on 1)

The DNA aptamer of claim 1, comprising the nucleotide sequence of SEQ ID NO: 6.

### Claim 3 (depends on 1)

The DNA aptamer of claim 1, wherein the aptamer has been modified to have resistance to DNase.

### Claim 4 (depends on 3)

The DNA aptamer of claim 3, wherein the modification is substitution of —OH group at 2′ carbon of a sugar moiety in one or more nucleotides with -Me (methyl), —OMe, —NH2, —F (fluorine), —O-2-methoxyethyl-O-propyl, —O-2-methylthio ethyl, —O-3-aminopropyl, —O-3-dimethylaminopropyl, —O—N-methylacetamido or —O-dimethylamidoxyethyl.

### Claim 5 (depends on 3)

The DNA aptamer of claim 3, wherein the modification is found in at least 10% of the nucleotides in SEQ ID NO: 6.

### Claim 6 (depends on 3)

The DNA aptamer of claim 3, wherein the DNA aptamer has a nucleotide sequence of SEQ ID NOs: 8, 12, or 14.

### Claim 7 (depends on 1)

The DNA aptamer of claim 1, consisting of a nucleotide sequence having at least 90% homology to the nucleotide sequence of SEQ ID NO: 4.

### Claim 8 (depends on 1)

The DNA aptamer of claim 1, consisting of the nucleotide sequence of SEQ ID NO: 4.

### Claim 9 (depends on 1)

A composition for targeting cancer tissues, comprising a DNA aptamer of claim 1.

### Claim 10 (depends on 1)

A composition for diagnosing a cancer, comprising a DNA aptamer of claim 1.

### Claim 11 (depends on 1)

A composition for treating a cancer, comprising a DNA aptamer of claim 1.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the cancer is pancreatic cancer, colon cancer, liver cancer, lung cancer, brain tumor, oral cavity cancer, ovary cancer or breast cancer.

### Claim 13 (depends on 11)

The composition of claim 11, further comprising an anticancer agent conjugated with the DNA aptamer.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the anticancer agent is one or more selected from the group consisting of MMAE (monomethyl auristatin E), MMAF (monomethyl auristatin F), calicheamicin, mertansine, ravtansine, tesirine, doxorubicin, cisplatin, SN-38, duocarmycin, and pyrrolobenzodiazepine.

### Claim 15 (depends on 11)

The composition of claim 11, wherein the DNA aptamer is conjugated with a polyethylene glycol (PEG) or its derivative, a diacylglycerol (DAG) or its derivative, a dendrimer, an antibody, or a phosphorylcholine-containing polymer.

### Claim 16 (depends on 1)

A method of targeting cancer tissues, comprising administering the DNA aptamer of claim 1 to a subject in need thereof.

### Claim 17 (depends on 1)

A method of diagnosing a cancer, comprising administering the DNA aptamer of claim 1 which is conjugated with an imaging agent to a subject in need thereof, and detecting a signal released by the imaging agent to diagnose the cancer.

### Claim 18 (depends on 1)

A method of treating a cancer, comprising administering the DNA aptamer of claim 1 which is conjugated with an anticancer agent to a subject in need thereof.
